» Articles » PMID: 31909882

Blockade of High Mobility Group Box 1 Involved in the Protective of Curcumin on Myocardial Injury in Diabetes in Vivo and in Vitro

Overview
Journal IUBMB Life
Date 2020 Jan 8
PMID 31909882
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to investigate the protective effect of curcumin (Cu) on myocardial injury in diabetic cardiomyopathy in vivo and in vitro. Serum and myocardial glucose, inflammatory cytokines, and cardiac function indexes of type 2 diabetes db/db mice were measured. The mechanism of action was confirmed by immunohistochemistry, immunofluorescence, and western blot experiments. H9C2 cells stimulated by glucose (Glu) were used as cell models in vitro. Cu treatment improved glucose tolerance and lipid profile and reduced the production of inflammatory cytokines. In addition, Cu decreased the serum biochemical indexes. Cu inhibits high mobility group box 1 (HMGB1) signaling pathway in db/db mice. Cu treatment also significantly inhibited pa-induced inflammatory signaling pathway in H9C2 cells. HMGB1 inhibitor or HMGB1 knockdown counteracted the effects of Cu on diabetic cardiomyopathy. The present study showed the protective effects of Cu on myocardial injury via HMGB1 pathway in diabetic cardiomyopathy in vivo and in vitro.

Citing Articles

Review of the Protective Mechanism of Curcumin on Cardiovascular Disease.

Yang C, Zhu Q, Chen Y, Ji K, Li S, Wu Q Drug Des Devel Ther. 2024; 18:165-192.

PMID: 38312990 PMC: 10838105. DOI: 10.2147/DDDT.S445555.


Pharmacological Mechanisms and Clinical Applications of Curcumin: Update.

Hao M, Chu Y, Lei J, Yao Z, Wang P, Chen Z Aging Dis. 2023; 14(3):716-749.

PMID: 37191432 PMC: 10187702. DOI: 10.14336/AD.2022.1101.


[Dihydromyricetin improves cardiac insufficiency by inhibiting HMGB1 in diabetic rats].

Liu S, Liu Q, Peng Q, Zhang Y, Wang J Nan Fang Yi Ke Da Xue Xue Bao. 2022; 42(5):641-648.

PMID: 35673906 PMC: 9178629. DOI: 10.12122/j.issn.1673-4254.2022.05.03.